Pipeline

Powered by Molecule Pro™

Program	Target	Indication	Discovery	Optimization	IND-enabling	Phase I	Phase II	Phase III	Partner
Wholly Owned
MRANK-001	Small Molecule GLP-1RA	Obesity	Potential Best-in-Class
		Type 2 Diabetes	Potential Best-in-Class
MRANK-106	DNA Damage Repair	Pancreatic cancer, etc
MRANK-111	CB1R	Obesity, etc.
MRANK-101	P53	Oncology
MRANK-103 (formerly 002)	MYC-high	Oncology
MRANK-023	Undisclosed	Undisclosed
Co-Developed
2 programs	Undisclosed	Undisclosed							Public Biotech
8 programs	Undisclosed	Undisclosed
Design as a Service
EMRANK-016	Allosteric Inhibitor	Oncology	PCC delivered						Public Biotech
EMRANK-189	Undisclosed	Oncology	Lead delivered						Public Biotech